Program Update!

Effective January 1st, Genentech will be updating the co-pay program benefit period. The program will be moving from a 12-month benefit to a calendar year benefit (January to December).

Patient benefit will automatically renew annually for all patients enrolled in the program on January 1st.

For more information, please call the Help Desk at 844-672-6729.

The information contained in this section of the site is intended for US health care professionals and specialty pharmacy representatives only. Click “OK” if you are a health care professional or specialty pharmacy representative.

Indication and Important Safety Information  |  Prescribing Information

Please note: Depending on your insurance plan, you may owe more than $5. This program helps with the costs of OCREVUS only. It does not help with the cost of other medicines you take at the same time as OCREVUS or with facility fees.

Enroll Now

Have a temporary reference number and want to return to the confirmation screen?

Enter your information here:

Indication and Important Safety Information

What is OCREVUS?

OCREVUS is a prescription medicine used to treat:

  • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
  • Primary progressive MS, in adults.

It is not known if OCREVUS is safe and effective in children.

Who should not receive OCREVUS?

Do not receive OCREVUS if you have an active hepatitis B virus (HBV) infection.
Do not receive OCREVUS if you have had a life-threatening allergic reaction to OCREVUS. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or any of its ingredients in the past.

What is the most important information I should know about OCREVUS?

OCREVUS can cause serious side effects, including:

  • Infusion reactions: Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction.
  • Infection: OCREVUS increases your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Infections are a common side effect, which can be serious. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS until your infection is gone
  • Decreased immunoglobulins: OCREVUS may cause a decrease in some types of immunoglobulins. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

What are the possible side effects of OCREVUS?

OCREVUS may cause serious side effects, including:

  • Risk of cancers (malignancies) including breast cancer. Follow your healthcare provider’s instructions about standard screening guidelines for breast cancer.

These are not all the possible side effects of OCREVUS.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For more information, go to www.OCREVUS.com or call 1-844-627-3887.

For additional safety information, please see the full Prescribing Information and Medication Guide.

close

We are open from 9 a.m.–8 p.m. ET, Monday through Friday, except for the following holidays:

  • New Year's Day
  • Memorial Day
  • Independence Day
  • Labor Day
  • Thanksgiving Holiday (Thursday and Friday)
  • Christmas Holiday

Questions about this program?

Call (844) MS-COPAY (844-672-6729)
9 a.m.–8 p.m. ET, Monday through Friday (except major holidays)
 
For questions about OCREVUS, please call (844) OCREVUS (844-627-3887).

OCREVUS® and its logo are registered trademarks of Genentech, Inc.
 
©2021 Genentech USA, Inc.   All rights reserved.   M-US-00000248(v3.0)   01/21

Fax (855) MS-COPAY (855-672-6729)

Privacy Policy |  Cookie Preferences